Scott Burian, Ph.D.

Senior Research Scientist

Scott Burian

Scott Burian, Ph.D.

Senior Research Scientist

Dr. Burian has more than 15 years of experience in the pharmaceutical industry and has contributed to the development of a diverse range of small molecule, biologic, and nanoparticle-based products. He is a broadly-experienced regulatory affairs professional specializing in pharmaceutical development, regulatory strategy, and chemistry, manufacturing, and controls (CMC). Dr. Burian has supported the development of lingual spray, solid oral, topical, parenteral, and nasal spray dosage forms. Prior to joining Rho in early 2016, Dr. Burian served as the Director, Regulatory Affairs CMC at Mallinckrodt Pharmaceuticals.  In this role, he provided input into drug substance and drug product development plans, authored CMC related documentation for regulatory submissions, provided input on regulatory strategies related to CMC, participated in FDA interactions, and performed man-in-the-plant activities at contract manufacturing organizations.  Prior to Mallinckrodt Pharmaceuticals, Dr. Burian held Director of CMC Regulatory Affairs positions at Kowa Research Institute and Cato Research from 2002 through 2015.

Dr. Burian earned a doctorate in pharmacology from Wake Forest University School of Medicine in 2002 and has maintained the Regulatory Affairs Certification from RAPS since 2012.  Prior to pursuing his doctoral degree, from 1995 through 1997, he worked as a Drug Manufacturing Technician and Production Manager at Cambridge Biotech Corporation and Cornell University Duck Research Laboratory.